With the explosion in novel cancer therapies, cancer outcomes have improved dramatically resulting in a growing population of cancer survivors. Simultaneously, there has been a rise in cardiovascular side effects of these cancer therapies that are limiting the quality of life and life expectancy of cancer survivors. The Tufts Cardio-Oncology Research Group is hosted by the Molecular Cardiology Research Institute (MCRI). Since 2017, the Cardio-Oncology Research Group has been bringing together basic scientists from the MCRI with clinician-investigators from the Cardiology and Oncology Divisions at Tufts Medical Center and at the Cummings School of Veterinary Medicine at Tufts University along with scientists at Tufts University Schools of Medicine and Engineering and statisticians and population researchers in the Institute for Clinical Research and Health Policy Studies (ICRHPS) and the Tufts Clinical and Translational Sciences Institute (CTSI). Together, the goal of the Cardio-oncology Research Group is to advance our understanding of genetic, biological, and clinical factors that contribute to the cardiovascular side effects of cancer therapies, to identify biomarkers of toxicity that can be employed to improve clinical care and to determine therapies to mitigate the side effects of cancer treatment. The group is using a one-health approach to develop a cross-species platform that includes cellular and model organisms, canine cancer patients, and human cancer patients to investigate novel mechanisms, biomarkers, and therapies to improve cardiovascular outcomes in cancer patients.
Faculty sponsor: Iris Jaffe, MD, PhD
Email: Iris.Jaffe@tuftsmedicine.org